EGFR突变的非小细胞肺癌患者应用EGFR TKI治疗的疗效:针对13项随机试验的Meta分析结果
Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. The purpose of this meta-analysis was to evaluate the benefit of EGFR TKIs in EGFR-mutated NSCLCs. Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. The mutational status was obtained through a retrospective or prospective analysis. Relative risk (RR) was calculated for response rate, and hazard ratios (HRs) were calculated for progression-free and overall survival. EGFR TKIs increase the chance of obtaining an objective response almost 2-fold when compared with chemotherapy (RR, 2.06; 2p < .00001). The response rate was 70% vs. 33.2% in first-line trials. In 3 second-line trials, response rates were 47.4% vs. 28.5%, with a benefit similar to first-line trials (RR, 1.79; 2p = .04). EGFR TKIs reduced the hazard of progression by 70% in all trials (HR, 0.30; 2p < .00001) and by 65% in first-line trials only (HR, 0.35; 2p < .00001). Overall, however, they do not improve survival (HR, 0.96; 2p = .71). NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. All patients affected by NSCLC with an EGFR-positive mutation test result must be offered the opportunity to be treated with an EGFR TKI upfront or during the natural course of the disease if not previously exposed.
结论:对于EGFR突变阳性的非小细胞肺癌患者,若此前未给予EGFR TKI治疗,则必须考虑优先接受该类药物的治疗。注:本文主要考查了罗氏的特罗凯和AZ的易瑞沙,但结果对特罗凯更有利。
上一篇: 肝menin可募集SIRT1以通过组蛋白脱乙酰化而控制肝脂肪变性
下一篇: 含有屈螺酮的复合口服避孕药(24天方案)的心血管安全性和整体安全性:来自女性使用口服避孕药活动监测国际组织的最终研究结果
- 您可能感兴趣的文章
-